Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL

13 Oct 2005

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 16224487
DOI: 10.1038/sj.leu.2403983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABLPMID 16224487Read ↗

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatmentSemantic proximity Read ↗

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapySemantic proximity Read ↗

Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL.Semantic proximity Read ↗

Semi‑random mutagenesis profile of BCR‑ABL during imatinib resistance acquirement in K562 cells.Semantic proximity Read ↗

Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.Semantic proximity Read ↗

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinibSemantic proximity Read ↗

Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.Semantic proximity Read ↗

BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib TreatmentSemantic proximity Read ↗

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinibSemantic proximity Read ↗

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.Semantic proximity Read ↗

Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populationsSemantic proximity Read ↗

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.